Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

[LDL-cholesterol goals and changes in C reactive protein in high coronary risk patients].

Costa JA, Rodilla E, Pérez-Lahiguera F, Miralles A, González C, Pascual JM.

Rev Clin Esp. 2009 Oct;209(9):415-23. Spanish.

PMID:
19852909
2.

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.

Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K.

Vasc Health Risk Manag. 2013;9:719-27. doi: 10.2147/VHRM.S49840. Epub 2013 Nov 15.

3.

Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy.

González CA, Rubio-Guerra AF, Pavía A, Redding FJ, Cervantes JL, Zacarías JL, Yza R, Carranza J, Fernández P, Morales E, Robles FJ, Leyva JL, Rodríguez L.

Clin Drug Investig. 2007;27(5):333-7.

PMID:
17451281
4.

Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.

Pearson TA, Ballantyne CM, Veltri E, Shah A, Bird S, Lin J, Rosenberg E, Tershakovec AM.

Am J Cardiol. 2009 Feb 1;103(3):369-74. doi: 10.1016/j.amjcard.2008.09.090. Epub 2008 Oct 30.

PMID:
19166691
5.

Second-line treatments for dyslipidemia in patients at risk of cardiovascular disease.

Kondo Y, Hamai J, Nezu U, Shigematsu E, Kamiko K, Yamazaki S, Yoshii T, Takahashi M, Takano T, Kawasaki S, Yamada M, Yamakawa T, Terauchi Y.

Endocr J. 2014;61(4):343-51. Epub 2014 Jan 22.

7.

Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.

Ambegaonkar BM, Tipping D, Polis AB, Tomassini JE, Tershakovec AM.

Atherosclerosis. 2014 Dec;237(2):829-37. doi: 10.1016/j.atherosclerosis.2014.10.105. Epub 2014 Nov 4.

PMID:
25463129
8.

Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.

Toth PP, Ballantyne CM, Davidson MH, Tomassini JE, Ramey DR, Neff D, Tershakovec AM, Hu XH, Tunceli K.

J Clin Lipidol. 2012 Mar-Apr;6(2):180-91. doi: 10.1016/j.jacl.2011.11.007. Epub 2011 Dec 7.

PMID:
22385552
9.
10.

How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.

Barkas F, Milionis H, Kostapanos MS, Mikhailidis DP, Elisaf M, Liberopoulos E.

Curr Med Res Opin. 2015 Feb;31(2):221-8. doi: 10.1185/03007995.2014.982751. Epub 2014 Nov 24.

PMID:
25418708
11.

Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.

Yamazaki D, Ishida M, Watanabe H, Nobori K, Oguma Y, Terata Y, Koyama T, Iino K, Kosaka T, Ito H.

Lipids Health Dis. 2013 Feb 4;12:9. doi: 10.1186/1476-511X-12-9.

12.

Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.

Toth PP, Foody JM, Tomassini JE, Sajjan SG, Ramey DR, Neff DR, Tershakovec AM, Hu XH, Tunceli K.

J Clin Lipidol. 2014 Jan-Feb;8(1):107-16. doi: 10.1016/j.jacl.2013.09.009. Epub 2013 Oct 1.

PMID:
24528691
14.

Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.

Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E.

Circulation. 2015 Sep 29;132(13):1224-33. doi: 10.1161/CIRCULATIONAHA.115.018381. Epub 2015 Sep 1.

PMID:
26330412
15.

Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients.

Thongtang N, Lin J, Schaefer EJ, Lowe RS, Tomassini JE, Shah AK, Tershakovec AM.

Atherosclerosis. 2012 Dec;225(2):388-96. doi: 10.1016/j.atherosclerosis.2012.09.001. Epub 2012 Sep 13.

16.

An observational study of ezetimibe in cardiac transplant recipients receiving calcineurin inhibitors.

Makkar KM, Sanoski CA, Goldberg LR, Spinler SA.

Ann Pharmacother. 2013 Nov;47(11):1457-62. doi: 10.1177/1060028013504077.

PMID:
24285762
17.

Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers.

Wu NQ, Guo YL, Zhu CG, Gao Y, Zhao X, Sun D, Sun J, Xu RX, Liu G, Dong Q, Li JJ.

Lipids Health Dis. 2018 Nov 23;17(1):265. doi: 10.1186/s12944-018-0909-z.

18.

Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.

Hagiwara N, Kawada-Watanabe E, Koyanagi R, Arashi H, Yamaguchi J, Nakao K, Tobaru T, Tanaka H, Oka T, Endoh Y, Saito K, Uchida T, Matsui K, Ogawa H.

Eur Heart J. 2017 Aug 1;38(29):2264-2276. doi: 10.1093/eurheartj/ehx162.

19.
20.

Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.

Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E; Ezetimibe Study Group.

Am Heart J. 2004 Sep;148(3):447-55.

PMID:
15389231

Supplemental Content

Support Center